Innovative Therapies for Children with Cancer
A PHASE I/II, MULTICENTER, OPEN-LABEL, MULTI-ARM STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PRELIMINARY ACTIVITY OF IDASANUTLIN
A Phase Ib study of Vyxeos® (liposomal daunorubicin and cytarabine) in combination with Clofarabine in children with relapsed/refractory AML
An Open-Label, Single-Arm, Phase 1/2 Study Evaluating the Safety and Efficacy of Single- Agent Ponatinib for the Treatment of advanced Leukemias or Solid Tumors in Pediatric Participants
Phase 1b/2 Study of Carfilzomib in combination with Dexamethasone, Mitoxantrone, PEG-asparaginase, and Vincristine (R3 Induction Backbone) in pediatric subjects with relapsed or refractory Acute Lymphoblastic Leukemia
A Prospective, Multicentric Clinical Proof-of-Concept Study to Stratify Targeted Therapies Adapted to Molecular Profiling of Relapsed or Refractory Pediatric Tumors
European Proof-of-Concept Therapeutic Stratification Trial of Molecular Anomalies in Relapsed or Refractory Tumors in children
Ibrutinib randomized safety and efficacy study in pediatric patients with mature B-cell NHL, including Burkitt lymphoma/Leukemia and Diffuse Large B-cell Lymphoma
A Phase 1 Study of Aurora Kinase A Inhibitor LY3295668 Erbumine as a Single Agent and in Combination in Patients With Relapsed/Refractory Neuroblastoma
